



ANALYSIS C-1
Current Fund Revenues
 For the year ended June 30, 2011

	<u>Total</u>	<u>Unrestricted</u>	<u>Restricted</u>
State appropriations~			
General	\$ 11,925,105	\$ 11,925,105	\$ -
Dedicated	93,787	93,787	-
Total state appropriations	<u>12,018,892</u>	<u>12,018,892</u>	<u>-</u>
Government grants and contracts~			
Federal	19,664,144	-	19,664,144
State	862,916	-	862,916
Total government grants and contracts	<u>20,527,060</u>	<u>-</u>	<u>20,527,060</u>
Private grants and contracts	<u>10,366,254</u>	<u>-</u>	<u>10,366,254</u>
Gifts	<u>2,352,227</u>	<u>-</u>	<u>2,352,227</u>
Endowment	<u>855,639</u>	<u>-</u>	<u>855,639</u>
Sales and services of educational departments~			
Clinical and chemical analysis	9,230	9,230	-
Exercise testing core	20,957	20,957	-
Genomics core lab	11,748	11,748	-
Miscellaneous	1,565	1,565	-
Molecular genetics	5,780	5,780	-
Transgenics core lab	30,000	30,000	-
Total sales and services of educational departments	<u>79,280</u>	<u>79,280</u>	<u>-</u>
Auxiliary enterprise revenues~	<u>2,266,078</u>	<u>-</u>	<u>2,266,078</u>
Other sources~			
Interest on investments	136,523	-	136,523
Miscellaneous	7,045	11,087	(4,042)
Recovery of indirect costs	7,703,046	735,554	6,967,492
Royalties	(2,081)	-	(2,081)
Total other sources	<u>7,844,533</u>	<u>746,641</u>	<u>7,097,892</u>
Total revenues	<u><u>\$ 56,309,963</u></u>	<u><u>\$ 12,844,813</u></u>	<u><u>\$ 43,465,150</u></u>